Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With RAS-mutated Metastatic Colorectal Cancer: a Dose-escalation, Phase I/II Trial
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Fluorouracil (Primary) ; Irinotecan (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary) ; Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; First in man
- Acronyms FOLFIRINOX-R
- 01 Sep 2024 Results assessing safety published in the Cancer Chemotherapy and Pharmacology
- 08 Feb 2024 Planned End Date changed from 31 Oct 2024 to 30 Nov 2024.
- 03 Jul 2023 Planned End Date changed from 31 Dec 2023 to 31 Oct 2024.